Leleux Press Review Friday 23/1/2015 BEL 20 (Belgium) Last Price 3456,95 Minimum Price 1046,07 (02/09/1992) Maximum Price 4759,01 (23/05/2007) Gainers 15 Losers 5 GDF SUEZ (FR) 19,28 +3,07% DELHAIZE GROUP (BE) 66,61 -1,63% GBL (BE) 73,01 +2,31% UCB 68,33 -1,41% D'IETEREN (BE) 29,98 +1,71% BPOST 22,25 -0,73% CAC 40 (France) Last Price 4552,80 Minimum Price 2693,21 (23/09/2011) Maximum Price 7347,94 (21/10/2009) Gainers 34 Losers 6 SAINT GOBAIN (FR) 37,97 +5,10% GEMALTO N.V. 63,11 -2,71% ALCATEL-LUCENT (FR) 2,99 +5,08% ESSILOR INTL (FR) 96,78 -2,59% RENAULT SA 67,52 +3,78% PERNOD RICARD 102,25 -0,82% AEX (Nederland) Last Price 447,77 Minimum Price 194,99 (09/03/2009) Maximum Price 806,41 (21/10/2009) Gainers 21 Losers 4 PHILIPS ELECTRONICS 26,24 +2,92% GEMALTO N.V. 63,11 -2,71% FUGRO 17,24 +2,86% HEINEKEN NV 62,68 -0,47% RANDSTAD (NL) 44,47 +2,71% TNT EXPRESS 5,53 -0,10% DAX (Deutschland) Last Price 10435,62 Minimum Price 438,38 (18/03/2002) Maximum Price 636497,44 (18/03/2011) Gainers 25 Losers 5 LANXESS AG 37,76 +3,97% FRESENIUS MED CARE ( 63,51 --1,09% CONTINENTAL (DE) 201,55 +3,54% FRESENIUS SE & CO (D 48,03 --1,03% BMW AG (DE) 98,04 +3,28% LUFTHANSA (DE) 15,16 --0,26% Dow Jones Industries (United States) Last Price 17813,98 Minimum Price 0,20 (21/10/2011) Maximum Price 19737,03 (02/11/2011) Gainers 27 Losers 3 UNITEDHEALTH GROUP 113,85 +4,14% AMERICAN EXPRESS (US 84,37 -3,76% JP MORGAN CHASE (US) 57,59 +3,04% VERIZON COMM (US) 47,80 -0,93% TRAVELLERS CAS INC 108,17 +3,00% AT&T INC. 33,79 -0,61% Page 1 of 12 Leleux Press Review Friday 23/1/2015 E:BSLN - BASILEA N - CHF Basilea announces that FDA's Anti-Infective Drugs Advisory C Thomson Reuters (22/01/2015) Basilea Pharmaceutica AG / Basilea announces that FDA's Anti-Infective Drugs Advisory Committee recommendsapproval of isavuconazole for the treatment of invasive aspergillosis andmucormycosis . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. Basel, Switzerland, January 22, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN)today announced that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee voted unanimously to recommend approval ofthe investigational once-daily intravenous and oral antifungal isavuconazole,the active moiety of the prodrug isavuconazonium sulfate, for the treatment ofinvasive aspergillosis, and eight to two with one abstention to recommendapproval for the treatment of invasive mucormycosis (also known as zygomycosis),life-threatening fungal infections predominantly occurring in immunocompromisedpatients. Basilea's partner Astellas presented the data to the FDA and, ifapproved, intends to market the drug as Cresemba(®) in the United States. 'The Advisory Committee's positive vote is an important regulatory step in theongoing FDA review of isavuconazole,' said Ronald Scott, Basilea's ChiefExecutive Officer. The Advisory Committee's recommendation is based on data from the isavuconazoledevelopment program, which included analyses from two phase 3 clinical trials inadult patients with invasive fungal infections: SECURE, a randomized, double-blind, active-control study of adult patients with invasive aspergillosis, andVITAL, an open-label non-comparative study of isavuconazole in adult patientswith invasive aspergillosis and renal impairment or in patients with invasivefungal disease caused by other fungi, including those causing mucormycosis. The Advisory Committee provides the FDA with independent expert advice andrecommendations. The FDA is not bound by the Advisory Committee'srecommendations, but its input will be considered by the FDA in its review ofthe isavuconazole New Drug Application (NDA), which was submitted by asubsidiary of Basilea's licensing partner Astellas Pharma Inc. on July 8, 2014.The Prescription Drug User Fee Act (PDUFA) date for the isavuconazole NDA isMarch 8, 2015, which is the target date for the FDA to complete its review. For additional information on the January 22, 2015 Advisory Committee meetingplease visit http://www.fda.gov/AdvisoryCommittees/Calendar/ucm424436.htm. Isavuconazole is also currently under regulatory review by the EuropeanMedicines Agency (EMA) for the treatment of invasive aspergillosis andmucormycosis in adults. The regulatory review of the Marketing AuthorizationApplication (MAA), which was submitted by Basilea on July 16, 2014, isanticipated to be completed in the fourth quarter of 2015. Enrollment of patients into a third phase 3 study, ACTIVE, which assessesisavuconazole in the treatment of candidemia and other invasive Candidainfections, was completed in January 2015 and topline data are anticipated forthe second half of this year, following completion of treatment and follow-upperiods. About isavuconazole Isavuconazole is an investigational product and not approved for commercial usein any markets - it is currently under review by the FDA and the EMA. Conference call Basilea Pharmaceutica Ltd. invites you to participate in a conference call onFriday, January 23, 2015, 4 p.m. (CET), during which the company will discusstoday's press release. Dial-in numbers are: +41 (0) 58 310 5000 (Europe and ROW) +1 (1) 631 570 5613 (USA) +44 (0) 203 059 5862 (UK) A playback will be available 1 hour after the conference call until Monday,January 26, 2015, 6 p.m. (CET). Participants requesting a digital playback maydial: +41 (0) 91 612 4330 (Europe and ROW) +1 (1) 866 416 2558 (USA) +44 (0) 207 108 6233 (UK) and will be asked to enter the ID 11607 followed by the # sign. About Basilea Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing productsthat address increasing resistance and non-response to current treatment optionsin the therapeutic areas of bacterial infections, fungal infections and cancer.The company uses the integrated research, development and commercial operationsof its subsidiary Basilea Pharmaceutica International Ltd. to develop andcommercialize innovative pharmaceutical products to meet the medical needs ofpatients with serious and potentially life-threatening conditions. BasileaPharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIXSwiss Exchange (SIX: BSLN). Additional information can be found at Basilea'swebsite www.basilea.com. Disclaimer This communication expressly or implicitly contains certain forward-lookingstatements concerning Basilea Pharmaceutica Ltd. and its business. Suchstatements involve certain known and unknown risks, uncertainties and otherfactors, which could cause the actual results, financial condition, performanceor achievements of Basilea Pharmaceutica Ltd. to be materially different fromany future results, performance or achievements expressed or implied by suchforward-looking statements. Basilea Pharmaceutica Ltd. is providing thiscommunication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, futureevents or otherwise. For further information, please contact: +-----------------------------+--------------------------------+ Media Relations Investor Relations +-----------------------------+---- ----------------------------+ ... (truncated) ... Page 2 of 12 Leleux Press Review Friday 23/1/2015 TER - TERREIS - EUR Terreïs: activité en nette hausse en 2014. Cercle Finance (22/01/2015) (CercleFinance.com) - Terreïs a enregistré une progression de 16,4% de ses revenus annuels à 71,9 millions d'euros. Le segment 'Bureaux/commerces' a généré 66,8 millions d'euros de chiffre d'affaires, en hausse de 19,8% par rapport à l'exercice 2013, tandis que la branche résidentielle a accusé un repli de 15,3% de ses revenus à 5,1 millions. Sur le seul quatrième trimestre, le chiffre d'affaires de Terreïs s'est établi à 18,1 millions d'euros, soit une hausse de 15,1%, dont 17 millions dans le pôle 'Bureaux/commerces' (+18,3%) et 1,1 million dans l'activité résidentielle (-18%). Sur l'ensemble de l'année, le taux d'occupation financière du patrimoine tertiaire, qui intègre la vacance technique d'immeubles en cours de travaux, est ressorti à 95,3%, stable par rapport à 2013. Le patrimoine de Terreïs s'établissait par ailleurs à près de 1,6 milliard d'euros au 31 décembre dernier, en augmentation de 12 % sur un an. Cette progression de 168 millions d'euros est due aux acquisitions (+85,3 millions d'euros) et plus encore à la réévaluation du patrimoine (+116,6 millions d'euros), lesquelles ont compensé les 33,7 millions d'euros de cessions (en valeur d'expertise) opérées en 2014. A terme, Terreïs escompte accroître son portefeuille tertiaire parisien et se concentrer sur Paris QCA. Dans les conditions actuelles du marché prime parisien, le groupe - tout en restant attentif aux opportunités qui pourraient se présenter - se concentrera sur la cession dans les meilleures conditions de ses actifs non stratégiques (résidentiels, province et Île-de- France). OPN - GROUPE OPEN - EUR Groupe Open: vise une forte augmentation de ses résultats. Cercle Finance (22/01/2015) (CercleFinance.com) - Le chiffre d'affaires 2014 s'inscrit à 264,4 ME, en croissance de +7% (+4,6% en organique). Le 4ème trimestre affiche une croissance de chiffre d'affaires de +7,4% à 63,9 ME (+4,3% en organique). L'activité à l'international enregistre sur le trimestre une croissance de +15%. ' Cette croissance annuelle de chiffre d'affaires s'explique par la confirmation de l'amélioration du taux d'occupation, par la stabilité du Taux Journalier Moyen ainsi que par la croissance des effectifs productifs ' indique le groupe. Le groupe anticipe une forte augmentation de sa marge d'exploitation et de ses résultats 2014. ' La solidité de cette performance et la visibilité générée par l'embarqué des contrats et des effectifs confortent Groupe Open dans sa perspective de croissance de chiffre d'affaires et de résultats pour les années à venir ' indique la direction. EDF - EDF - EUR EDF EN: mise en service d'un parc éolien au Texas.